The largest corporate Bitcoin holder added 811 BTC to its treasury, spending $65.5 million, while repurchasing $208.2 million of its preferred shares—over three times the Bitcoin purchase amount. This shift highlights a growing focus on managing preferred stock liquidity alongside Bitcoin accumulation. The company’s Bitcoin holdings stand at 848,517 BTC with an average cost of $75,446 per coin. Prioritizing preferred stock buybacks may stabilize that market segment but reduces capital available for Bitcoin purchases.
The strategy's recent Bitcoin purchase and preferred share repurchase provide context for cryptocurrency market activity. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Nov 02, 2026 19:42 WIB: out of 50 priced major cryptocurrencies tradable on Pluang, 7 rose and 42 fell today. Notable movers include EGLD at Rp60.408 with a 1-day change of -3.71% and Pluang order activity showing 95% Sell / 5% Buy, THETA at Rp2.786 with a 1-day change of -3.70%, and SNX at Rp3.230 with a 1-day change of -3.32%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
